Eli Lilly
At Some Hospitals, Expert Panels Help Guide Anti-Amyloid Drug Decisions for Alzheimer's Patients
Premium
These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such programs are necessary.
Eli Lilly to Acquire Scorpion Therapeutics' Mutant PI3Kα Inhibitor for $2.5B
Lilly recently terminated its own mutant PI3Kα inhibitor program following disappointing Phase I results.
Ovation.io Collecting WGS, Clinical Data From 8,500 Patients on GLP-1 Meds
The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.
FDA Approves Pfizer's Braftovi With Eli Lilly's Erbitux, Chemo in Colorectal Cancer
The agency granted accelerated approval to the regimen as a frontline option for advanced, BRAF V600E-mtuated tumors based on the BREAKWATER trial.
Eli Lilly's SERD Benefits Endocrine-Resistant Breast Cancer Patients as Single-Agent, Combination
Premium
Imlunestrant by itself benefited those with ESR1 mutations but also had broad efficacy in ER-positive HER2-negative tumors when combined with a CDK4/6 inhibitor.
Nov 20, 2024
Jul 31, 2024
May 29, 2024
FDA Lowers Pediatric Age for Eli Lilly's Retevmo
Apr 8, 2024
Apr 4, 2024